City of Hope Comprehensive Cancer Center

Beckman Research Institute

Duarte, CA

Accepting patients

CA088-1005

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Learn more
  • CAR T Cell
  • CELMoD
  • GPRC5D
  • Phase 1

Accepting patients

BMS-986453

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • GPRC5D
  • Phase 1

Accepting patients

CS1-CAR T Cells

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
Learn more
  • CAR T Cell
  • SLAMF7
  • Phase 1

Not currently accepting

CAMMA-1

Phase 1B Clinical Trial Studying the Safety, Activity, and Effectiveness of Cevostamab in Treating People with Relapsed or Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • FCRH5
  • Phase 1

Accepting patients

Leflunomide

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Learn more
  • Disease-Modifying Antirheumatic Drug
  • Phase 2

Accepting patients

Mezigdomide Post Abecma Treatment

A Phase 1 Study of Mezigdomide (CC-92480) and Dexamethasone Post Idecabtagene Vicleucel in Relapsed Multiple Myeloma
Learn more
  • CELMoD
  • Maintenance
  • Phase 1

Accepting patients

FT576

FT576 in Subjects With Multiple Myeloma
Learn more
  • Natural Killer Cells (Allogeneic)
  • Phase 1
  • Has results

Not currently accepting

DRAMMATIC

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Learn more
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Phase 3

Accepting patients

JNJ-79635322

Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
Learn more
  • BCMA
  • GPRC5D
  • Tri-specific Antibody
  • Phase 1

Accepting patients

BGB-11417

A Phase 1b/2 Study of BGB-11417 in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
Learn more
  • BCL-2 Inhibitor
  • Phase 1/2
  • Has results
7 hidden based on your filters. Show All

Filters

Diagnosis

Treatment History

BCMA Therapy

Advanced Filters

Trial Enrollment Status

Classifications

Targets

Trial Type

Phase